Jill Gilbert

9.0k total citations · 2 hit papers
91 papers, 4.5k citations indexed

About

Jill Gilbert is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Otorhinolaryngology. According to data from OpenAlex, Jill Gilbert has authored 91 papers receiving a total of 4.5k indexed citations (citations by other indexed papers that have themselves been cited), including 49 papers in Oncology, 42 papers in Pulmonary and Respiratory Medicine and 40 papers in Otorhinolaryngology. Recurrent topics in Jill Gilbert's work include Head and Neck Cancer Studies (40 papers), Lung Cancer Treatments and Mutations (20 papers) and Oral health in cancer treatment (13 papers). Jill Gilbert is often cited by papers focused on Head and Neck Cancer Studies (40 papers), Lung Cancer Treatments and Mutations (20 papers) and Oral health in cancer treatment (13 papers). Jill Gilbert collaborates with scholars based in United States, Canada and Taiwan. Jill Gilbert's co-authors include Barbara A. Murphy, Barbara A. Murphy, Anthony J. Cmelak, Sheila H. Ridner, Christine H. Chung, David Quiceno, Juan B. Ochoa, Steven M. Dubinett, Claudia Patricia Pardo Hernández and Jovanny Zabaleta and has published in prestigious journals such as The Journal of Experimental Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Jill Gilbert

90 papers receiving 4.4k citations

Hit Papers

Pembrolizumab for Platinum- and Cetuximab-Refractory Head... 2017 2026 2020 2023 2017 2017 100 200 300 400
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study
    2017 497 citations Joshua Bauml, Tanguy Y. Seiwert et al. Journal of Clinical Oncology profile →
  2. E1308: Phase II Trial of Induction Chemotherapy Followed by Reduced-Dose Radiation and Weekly Cetuximab in Patients With HPV-Associated Resectable Squamous Cell Carcinoma of the Oropharynx— ECOG-ACRIN Cancer Research Group
    2017 317 citations Shanthi Marur, Shuli Li et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jill Gilbert United States 33 2.1k 1.3k 1.2k 1.1k 1.1k 91 4.5k
Seungwon Kim United States 36 1.8k 0.9× 1.6k 1.2× 831 0.7× 1.5k 1.3× 846 0.8× 119 4.0k
Xavier León Spain 32 1.3k 0.6× 1.5k 1.2× 1.0k 0.9× 1.5k 1.3× 630 0.6× 219 3.5k
Joseph Curry United States 32 1.1k 0.5× 599 0.5× 636 0.5× 1.2k 1.0× 1.1k 1.1× 238 3.6k
Alexandre Bozec France 29 845 0.4× 867 0.7× 833 0.7× 1.1k 1.0× 702 0.7× 158 2.9k
Susan G. Urba United States 39 2.8k 1.3× 2.1k 1.6× 3.4k 2.8× 3.7k 3.2× 826 0.8× 109 7.1k
Sjoukje F. Oosting Netherlands 31 1.1k 0.5× 618 0.5× 909 0.8× 590 0.5× 719 0.7× 113 3.0k
Mark Zafereo United States 41 1.6k 0.8× 1.2k 0.9× 942 0.8× 1.8k 1.5× 711 0.7× 192 4.9k
Judith C. McCaffrey United States 26 1.6k 0.8× 388 0.3× 491 0.4× 768 0.7× 886 0.8× 42 4.6k
Miriam N. Lango United States 27 886 0.4× 915 0.7× 575 0.5× 736 0.6× 602 0.6× 98 2.3k
Vincenzo Tombolini Italy 36 1.5k 0.7× 372 0.3× 1.4k 1.2× 953 0.8× 1.1k 1.0× 224 4.4k

Countries citing papers authored by Jill Gilbert

Since Specialization
Citations

This map shows the geographic impact of Jill Gilbert's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jill Gilbert with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jill Gilbert more than expected).

Fields of papers citing papers by Jill Gilbert

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jill Gilbert. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jill Gilbert. The network helps show where Jill Gilbert may publish in the future.

Co-authorship network of co-authors of Jill Gilbert

This figure shows the co-authorship network connecting the top 25 collaborators of Jill Gilbert. A scholar is included among the top collaborators of Jill Gilbert based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jill Gilbert. Jill Gilbert is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Rivero, Jaydira Del, Tobias Else, Julie Hallanger‐Johnson, et al.. (2024). A review of mitotane in the management of adrenocortical cancer. The Oncologist. 29(9). 747–760. 5 indexed citations
2.
Deng, Jie, Mary S. Dietrich, Kenneth J. Niermann, et al.. (2020). Refinement and Validation of the Head and Neck Lymphedema and Fibrosis Symptom Inventory. International Journal of Radiation Oncology*Biology*Physics. 109(3). 747–755. 26 indexed citations
3.
Mehnert, Janice M., Andréa Varga, Marcia S. Brose, et al.. (2019). Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced, PD-L1–positive papillary or follicular thyroid cancer. BMC Cancer. 19(1). 196–196. 148 indexed citations
4.
5.
Bauml, Joshua, Tanguy Y. Seiwert, David G. Pfister, et al.. (2017). Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study. Journal of Clinical Oncology. 35(14). 1542–1549. 497 indexed citations breakdown →
6.
Marur, Shanthi, Shuli Li, Anthony J. Cmelak, et al.. (2017). E1308: Phase II Trial of Induction Chemotherapy Followed by Reduced-Dose Radiation and Weekly Cetuximab in Patients With HPV-Associated Resectable Squamous Cell Carcinoma of the Oropharynx— ECOG-ACRIN Cancer Research Group. Journal of Clinical Oncology. 35(5). 490–497. 317 indexed citations breakdown →
7.
Gilbert, Jill, et al.. (2017). Ectopic, retroperitoneal adrenocortical carcinoma in the setting of Lynch syndrome. Familial Cancer. 17(3). 381–385. 12 indexed citations
8.
Bond, Stewart M., Mary S. Dietrich, Jill Gilbert, et al.. (2016). Neurocognitive function in patients with head and neck cancer undergoing primary or adjuvant chemoradiation treatment. Supportive Care in Cancer. 24(10). 4433–4442. 20 indexed citations
9.
Galloway, Thomas J., Lori J. Wirth, A. D. Colevas, et al.. (2015). A Phase I Study of CUDC-101, a Multitarget Inhibitor of HDACs, EGFR, and HER2, in Combination with Chemoradiation in Patients with Head and Neck Squamous Cell Carcinoma. Clinical Cancer Research. 21(7). 1566–1573. 84 indexed citations
10.
Deng, Jie, et al.. (2015). Preliminary Testing of a Patient-Reported Outcome Measure for Recurrent or Metastatic Head and Neck Cancer. American Journal of Hospice and Palliative Medicine®. 33(4). 313–320. 4 indexed citations
11.
Puzanov, Igor, Colin R. Lindsay, Laura W. Goff, et al.. (2014). A Phase I Study of Continuous Oral Dosing of OSI-906, a Dual Inhibitor of Insulin-Like Growth Factor-1 and Insulin Receptors, in Patients with Advanced Solid Tumors. Clinical Cancer Research. 21(4). 701–711. 78 indexed citations
12.
Murphy, Barbara A., Nancy Wells, Stewart M. Bond, et al.. (2014). Caregiving burden in head and neck cancer.. Journal of Clinical Oncology. 32(15_suppl). e20678–e20678. 3 indexed citations
13.
Argiris, Athanassios, Musie Ghebremichael, Jill Gilbert, et al.. (2013). Phase III Randomized, Placebo-Controlled Trial of Docetaxel With or Without Gefitinib in Recurrent or Metastatic Head and Neck Cancer: An Eastern Cooperative Oncology Group Trial. Journal of Clinical Oncology. 31(11). 1405–1414. 147 indexed citations
14.
Rosen, Lee S., Igor Puzanov, Gregory Friberg, et al.. (2012). Safety and Pharmacokinetics of Ganitumab (AMG 479) Combined with Sorafenib, Panitumumab, Erlotinib, or Gemcitabine in Patients with Advanced Solid Tumors. Clinical Cancer Research. 18(12). 3414–3427. 30 indexed citations
15.
Hayes, D. Neil, Tawee Tanvetyanon, Monika K. Krzyzanowska, et al.. (2012). Phase II Efficacy and Pharmacogenomic Study of Selumetinib (AZD6244; ARRY-142886) in Iodine-131 Refractory Papillary Thyroid Carcinoma with or without Follicular Elements. Clinical Cancer Research. 18(7). 2056–2065. 120 indexed citations
16.
Marur, Shanthi, Ju‐Whei Lee, Anthony J. Cmelak, et al.. (2012). ECOG 1308: A phase II trial of induction chemotherapy followed by cetuximab with low dose versus standard dose IMRT in patients with HPV-associated resectable squamous cell carcinoma of the oropharynx (OP).. Journal of Clinical Oncology. 30(15_suppl). 5566–5566. 21 indexed citations
17.
Gilbert, Jill, Michelle A. Rudek, Michaela J. Higgins, et al.. (2012). A Phase I Trial of Erlotinib and Concurrent Chemoradiotherapy for Stage III and IV (M0) Squamous Cell Carcinoma of the Head and Neck. Clinical Cancer Research. 18(6). 1735–1742. 15 indexed citations
18.
Gilbert, Jill, Kirsten Haman, Mary S. Dietrich, et al.. (2011). Depression in patients with head and neck cancer and a functional genetic polymorphism of the serotonin transporter gene. Head & Neck. 34(3). 359–364. 16 indexed citations
19.
Chung, Christine H., Erin H. Seeley, Heinrich Röder, et al.. (2010). Detection of Tumor Epidermal Growth Factor Receptor Pathway Dependence by Serum Mass Spectrometry in Cancer Patients. Cancer Epidemiology Biomarkers & Prevention. 19(2). 358–365. 51 indexed citations
20.
Rodrı́guez, Paulo C., Claudia Patricia Pardo Hernández, David Quiceno, et al.. (2005). Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma. The Journal of Experimental Medicine. 202(7). 931–939. 469 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Seungwon Kim Breakdown of academic impact, for papers by Xavier León Breakdown of academic impact, for papers by Joseph Curry Breakdown of academic impact, for papers by Alexandre Bozec Breakdown of academic impact, for papers by Susan G. Urba Breakdown of academic impact, for papers by Sjoukje F. Oosting Breakdown of academic impact, for papers by Mark Zafereo Breakdown of academic impact, for papers by Judith C. McCaffrey Breakdown of academic impact, for papers by Miriam N. Lango Breakdown of academic impact, for papers by Vincenzo Tombolini
Rankless by CCL
2026